Patents Assigned to CAFA THERAPEUTICS LIMITED
  • T-CELL EXPRESSING CHIMERIC RECEPTOR
    Publication number: 20220016166
    Abstract: Provided is a T-cell expressing a chimeric receptor, wherein the chimeric receptor specifically recognizes BCMA, and the endogenous TCR molecule and the endogenous MHC molecule are silenced. Also provided is the use of the T-cell in the preparation of a drug for treating BCMA positive tumors.
    Type: Application
    Filed: September 23, 2019
    Publication date: January 20, 2022
    Applicant: CAFA THERAPEUTICS LIMITED
    Inventors: Zonghai LI, Zhaohui LIAO
  • METHOD FOR GENE EDITING OF CELL ON THE BASIS OF CRISPR/CAS SYSTEM
    Publication number: 20220017926
    Abstract: Provided is a method for gene editing of a cell on the basis of a CRISPR/Cas system. The Cas enzyme is a Cas9 enzyme having an enzyme activity of 0.1-1 nmol. Further provided are a method for constructing a universal T cell, a T cell so prepared and use thereof. TCR genes and MHC genes of a T cell are edited by means of gene editing technology. Further provided is a gRNA construct.
    Type: Application
    Filed: September 23, 2019
    Publication date: January 20, 2022
    Applicant: CAFA THERAPEUTICS LIMITED
    Inventors: Zonghai LI, Zhaohui LIAO
  • Immunologic effector cell of targeted CLD18A2, and preparation method and use thereof
    Patent number: 11198729
    Abstract: Disclosed are a chimeric antigen receptor (CAR) targeting CLD18A2, and preparation method and use thereof. The extracellular binding region of the CAR comprises a protein specifically recognizing CLD18A2. The immune effector cell modified by the CAR can be used to treat tumors such as pancreatic cancer and stomach cancer.
    Type: Grant
    Filed: June 21, 2019
    Date of Patent: December 14, 2021
    Assignee: Cafa Therapeutics Limited
    Inventors: Huamao Wang, Bo Song, Xiumei Cai
  • METHOD FOR TREATING TUMOR USING IMMUNE EFFECTOR CELL
    Publication number: 20210292427
    Abstract: Provided is an immune effector cell expressing a chimeric antigen receptor that confers an individual specific recognization of BCMA, and a therapeutic method using the immune effector cell. The method improves the efficacy of immune effector cells in tumor treatments.
    Type: Application
    Filed: July 24, 2019
    Publication date: September 23, 2021
    Applicant: CAFA THERAPEUTICS LIMITED
    Inventors: Zonghai LI, Huamao WANG
  • Antibody for anti-claudin 18A2 and use thereof
    Patent number: 11111295
    Abstract: Provided in the present invention is an antibody for anti-claudin 18A2 and an immune effector cell targeting claudin 18A2. Also provided are methods for inducing cell death and treating tumours.
    Type: Grant
    Filed: July 10, 2017
    Date of Patent: September 7, 2021
    Assignee: CAFA THERAPEUTICS LIMITED
    Inventors: Peng Wang, Hua Jiang, Linlin Yang, Zhimin Shi, Huamao Wang, Zonghai Li